First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: A retrospective analysis from the CLCG

Shu Nan Qi, Yong Yang, Yu Qin Song, Ying Wang, Xia He, Chen Hu, Li Ling Zhang, Gang Wu, Bao Lin Qu, Li Ting Qian, Xiao Rong Hou, Fu Quan Zhang, Xue Ying Qiao, Hua Wang, Gao Feng Li, Hui Qiang Huang, Yu Jing Zhang, Yuan Zhu, Jian Zhong Cao, Jun Xin WuTao Wu, Su Yu Zhu, Mei Shi, Li Ming Xu, Zhi Yong Yuan, Hang Su, Jun Zhu, Ye Xiong Li

Research output: Contribution to journalArticlepeer-review

Abstract

The present study investigated the survival benefit of non-anthracycline (ANT)-based vs ANTbased regimens in a large-scale, real-world cohort of patients with extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKTCL). Within the China Lymphoma Collaborative Group (CLCG) database (2000-2015), we identified 2560 newly diagnosed patients who received chemotherapy with or without radiotherapy. Propensity score matching (PSM) and multivariable analyses were used to compare overall survival (OS) and progression-free survival (PFS) between the 2 chemotherapy regimens. We explored the survival benefit of non-ANT-based regimens in patientswith different treatments in early-stage disease and in riskstratified subgroups. Non-ANT-based regimens significantly improved survivals compared with ANT-based regimens. The 5-year OS and PFS were 68.9% and 59.5% for non-ANT-based regimens compared with 57.5% and 44.5% for ANT-based regimens in the entire cohort. The clinical advantage of non-ANT-based regimenswas substantial across the subgroups examined, regardless of stage and risk-stratified subgroup, and remained significant in early-stage patients who received radiotherapy. The survival benefits of non-ANT-based regimens were consistent after adjustment using multivariable and PSM analyses. These findings provide additional evidence supporting non-ANT-based regimens as a first-line treatment of patientswith ENKTCL.

Original languageEnglish (US)
Pages (from-to)3141-3153
Number of pages13
JournalBlood Advances
Volume4
Issue number13
DOIs
StatePublished - Jul 14 2020

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'First-line non-anthracycline-based chemotherapy for extranodal nasal-type NK/T-cell lymphoma: A retrospective analysis from the CLCG'. Together they form a unique fingerprint.

Cite this